Alyglo

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Alyglo
Generic name
HUMAN IMMUNOGLOBULIN G
Manufacturer
GC Biopharma Corp.
Product type
PLASMA DERIVATIVE
SPL set ID
fb97b3ec-29ee-4df1-aa99-c23e57a21228
SPL ID
7e2694c3-ad07-4724-8c50-d7eb4306b375
Version
5
Effective date
2025-06-05
Source export date
2026-11-13
Source partition
2
Source file
https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:32:06
Harmonized routes table
Harmonized routes
INTRAVENOUS

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE Thrombosis may occur with immune globulin (IGIV) products, including ALYGLO. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors [see Warnings and Precautions ( 5.2 ), Patient Counseling Information ( 17 )]. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IGIV products, including ALYGLO. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ALYGLO does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or acute renal failure, administer ALYGLO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity [see Dosage and Administration ( 2.3 ), Warnings and Precautions ( 5.3 , 5.4 )]. WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE See full prescribing information for complete boxed warning. Thrombosis may occur with immune globulin intravenous (IGIV) products, including ALYGLO. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Renal dysfunction, acute renal failure, osmotic nephropathy, and death may occur with the administration of IGIV products in predisposed patients. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. ALYGLO does not contain sucrose. For patients at risk of thrombosis, renal dysfunction or renal failure, administer ALYGLO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS IgA-deficient patients with antibodies to IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions to ALYGLO. Epinephrine should be available immediately to treat any severe acute hypersensitivity reactions ( 5.1 ). Thrombotic events have occurred in patients receiving IGIV treatments. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for patients at risk of hyperviscosity ( 5.2 , 5.4 ). Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure ( 5.3 ). Hyperproteinemia, increased serum viscosity, and hyponatremia or pseudohyponatremia may occur in patients receiving IGIV therapy ( 5.4 ). Aseptic meningitis syndrome (AMS) may occur, especially with high doses or rapid infusion ( 5.5 ). Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to IGIV treatments. Risk factors for hemolysis include high doses and non-O blood group. Closely monitor patients for hemolysis and hemolytic anemia ( 5.6 ). Monitor patients for pulmonary adverse reactions [transfusion-related acute lung injury (TRALI)] ( 5.7 ). ALYGLO is made from human plasma and may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent ( 5.8 ). 5.1 Hypersensitivity Severe hypersensitivity reactions may occur 1 . In case of hypersensitivity, discontinue ALYGLO infusion immediately and institute appropriate treatment. Have epinephrine available for immediate treatment of severe acute hypersensitivity reactions. ALYGLO contains trace amounts of IgA (≤ 20 mcg/mL) [ see Description ( 11 ) ] . Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. ALYGLO is contraindicated in IgA-deficient patients with antibodies against IgA or a history of hypersensitivity reaction [ see Contraindications ( 4 ) ] . 5.2 Thrombotic Events Thrombosis may occur following treatment with ALYGLO 2 , 3 , 4 . Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including patients with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. For patients at risk of thrombosis, administer ALYGLO at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity [ see Boxed Warning , Dosage and Administration ( 2 ) , Patient Counseling Information ( 17 ) ] . 5.3 Renal Failure Renal dysfunction, acute renal failure, osmotic nephropathy, and death5 may occur upon use of ALYGLO. Ensure that patients are not volume-depleted before administering ALYGLO. Monitor renal function and urine output periodically, especially in patients who are at higher risk of renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine before the initial infusion of ALYGLO and at appropriate intervals thereafter. If renal function deteriorates, consider discontinuing ALYGLO [ see Patient Counseling Information ( 17 ) ] . In patients who are at risk of developing renal dysfunction, because of pre-existing renal insufficiency or predisposition to acute renal failure (such as diabetes mellitus, hypovolemia, overweight, use of concomitant nephrotoxic medicinal products or age > 65 years), administer ALYGLO at the minimum infusion rate practicable [ see Boxed Warning , Dosage and Administration ( 2 ) ] . 5.4 Hyperproteinemia, Increased Serum Viscosity, and Hyponatremia Hyperproteinemia, increased serum viscosity, and hyponatremia may occur in patients receiving ALYGLO. It is critical to clinically distinguish true hyponatremia from a pseudohyponatremia that is associated with or causally related to hyperproteinemia with concomitant decreased calculated serum osmolality or elevated osmolar gap. Such treatment aimed at decreasing serum free water in patients with pseudohyponatremia may lead to volume depletion, a further increase in serum viscosity, and a possible predisposition to thrombotic events 6 . 5.5 Aseptic Meningitis Syndrome (AMS) AMS may occur with ALYGLO. AMS usually begins within several hours to 2 days following ALYGLO treatment. Discontinuation of treatment has resulted in remission of AMS within several days without sequelae 7 , 8 , 9 . AMS may occur more frequently with high doses (2 g/kg) and/or rapid infusion of ALYGLO. AMS is characterized by the following signs and symptoms: Severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea, and vomiting [ see Patient Counseling Information ( 17 ) ] . Cerebrospinal fluid (CSF) studies frequently reveal pleocytosis up to several thousand cells per cubic millimeter, predominantly from the granulocytic series, and elevated protein levels up to several hundred mg/dL, but negative culture results. Conduct a thorough neurological examination on patients exhibiting such signs and symptoms, including CSF studies, to rule out other causes of meningitis. 5.6 Hemolysis ALYGLO may contain blood group antibodies that can act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin test (DAT) (Coombs test) result and hemolysis 10 , 11 , 12 . Delayed hemolytic anemia due to enhanced RBC sequestration, and acute hemolysis, consistent with intravascular hemolysis, have been reported. Cases of severe hemolysis-related renal dysfunction/failure or disseminated intravascular coagulation have occurred following infusion of IGIV. The following risk factors may be associated with the development of hemolysis following IGIV administration: High doses (e.g., 2 g/kg or more), given either as a single administration or divided over several days, and non-O blood group 13 . Other individual patient factors, such as an underlying inflammatory state (as may be reflected by, for example, elevated C-reactive protein or erythrocyte sedimentation rate), have been hypothesized to increase the risk of hemolysis following administration of IGIV 14 , but their role is uncertain. Closely monitor patients for clinical signs and symptoms of hemolysis, particularly patients with risk factors noted above. Consider appropriate laboratory testing in higher risk patients, including measurement of hemoglobin or hematocrit. If clinical signs and symptoms of hemolysis or a significant drop in hemoglobin or hematocrit have been observed, perform confirmatory laboratory testing, including direct antiglobulin test. If transfusion is indicated for patients who develop hemolysis with clinically compromising anemia after receiving ALYGLO, perform adequate cross-matching to avoid exacerbating ongoing hemolysis. 5.7 Transfusion-Related Acute Lung Injury (TRALI) Noncardiogenic pulmonary edema [Transfusion-Related Acute Lung Injury (TRALI)] may occur in patients administered ALYGLO 15 . TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Signs and symptoms typically appear within 1 to 6 hours following treatment. Patients with TRALI may be managed using oxygen therapy with adequate ventilator support. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies and anti-human leukocyte antigen (HLA) antibodies in both the product and the patient's serum. 5.8 Transmissible Infectious Agents Because ALYGLO is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk of infectious agent transmission has been reduced by screening plasma donors and by including virus inactivation/removal steps in the manufacturing process of ALYGLO. Report all infections thought by a physician possibly transmitted by ALYGLO to GC Biopharma USA, Inc. at 1-833-426-6426. Discuss the risks and benefits of its use with the patient before prescribing or administering this product [ see Patient Counseling Information ( 17 )] . 5.9 Monitoring Laboratory Tests Periodic monitoring of renal function and urine output is particularly important in patients at increased risk of developing acute renal failure. Assess renal function, including measurement of blood urea nitrogen (BUN) and serum creatinine before the initial infusion of ALYGLO and at appropriate intervals thereafter. Because of the potential for increased risk of thrombosis with ALYGLO, consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, including those with cryoglobulins, fasting chylomicronemia/markedly high triacylglycerols (triglycerides), or monoclonal gammopathies. If signs and/or symptoms of hemolysis are present after an infusion of ALYGLO, perform appropriate laboratory testing for confirmation. Measure hemoglobin and/ or hematocrit at baseline and approximately 36 to 96 hours post-infusion in patients at higher risk of hemolysis. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient's serum. 5.10 Interference with Laboratory Tests After infusion of immunoglobulin, the transitory rise of the various passively transferred antibodies in the patient's blood may yield positive serological testing results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g., A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs) test.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 3 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions, observed in ≥ 5% of study subjects, were headache, nausea/vomiting, fatigue, nasal/sinus congestion, rash, arthralgia, diarrhea, muscle pain/aches, infusion site pain/swelling, abdominal pain/discomfort, cough, and dizziness. The most common adverse reactions, observed in ≥ 5% of study subjects, were headache, nausea/vomiting, fatigue, nasal/sinus congestion, rash, arthralgia, diarrhea, muscle pain/aches, infusion site pain/swelling, abdominal pain/discomfort, cough, and dizziness( 6 ). To report SUSPECTED ADVERSE REACTIONS, contact GC Biopharma USA, Inc. at 1-833-426-6426 or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In an open-label, single-arm, multicenter, non-randomized clinical trial, 33 subjects with primary humoral immunodeficiency received doses of ALYGLO (immune globulin intravenous, human-stwk) ranging from 319 mg/kg to 817 mg/kg every 21 days or 28 days for up to 12 months. Twenty-eight subjects (85%) experienced a total of 145 temporally associated adverse reactions (adverse events that occurred during or within 72 hours after the end of an infusion) during the study. The temporally associated ARs were headache (13 subjects, 39%), nausea/vomiting (11 subjects, 33%), fatigue (6 subjects, 18%), nasal/sinus congestion (5 subjects, 15%), rash (4 subjects, 12%), arthralgia, diarrhea (3 subjects, 9% each), muscle pain/aches, Infusion site pain/swelling, abdominal pain/discomfort, cough, dizziness (2 subjects, 6% each). These are presented in Table 2 . There were no deaths and no adverse reactions leading to withdrawal from the study. Table 2 Adverse Reactions* (ARs) (within 72 hours after the end of an ALYGLO infusion) in ≥ 5% of Subjects Adverse Reactions (ARs) No. of Subjects Reporting ARs (Percentage of Subjects) [N 1 =33] No. of Infusions with ARs (Percentage of Infusions) [N 2 =427] Headache 13 (39) 32 (7.5) Nausea/vomiting 11 (33) 20 (4.7) Fatigue 6 (18) 18 (4.2) Nasal/sinus congestion 5 (15) 5 (1.2) Rash 4 (12) 4 (0.9) Arthralgia 3 (9) 4 (0.9) Diarrhea 3 (9) 3 (0.7) Muscle pain/aches 2 (6) 7 (1.6) Infusion site pain/swelling 2 (6) 6 (1.4) Abdominal pain/discomfort 2 (6) 3 (0.7) Cough 2 (6) 2 (0.5) Dizziness 2 (6) 2 (0.5) * Adverse events that occurred during or within 72 hours after the end of an infusion 1 Total number of subjects 2 Total number of infusions 6.2 Postmarketing Experience Because postmarketing reporting of adverse reactions is voluntary and from a population of uncertain size, it is not always possible to reliably estimate the frequency of these reactions or establish a causal relationship to product exposure. The following adverse reactions have been identified and reported during the post-approval use of marketed IGIV products: Blood and lymphatic system disorders Leucopenia, hemolysis, pancytopenia Immune system disorders Hypersensitivity (e.g., anaphylaxis), anaphylactic shock, anaphylactic reaction, anaphylactoid reaction, allergic reaction, angioedema, face edema Metabolic and nutritional disorders Fluid overload, (pseudo) hyponatremia Psychiatric disorders Agitation, confusion, anxiety, nervousness Nervous system disorders Coma, loss of consciousness, seizures, (acute) encephalopathy, cerebrovascular accident, stroke, aseptic meningitis, migraine, speech disorder, paresthesia, hypoesthesia, photophobia, tremor Cardiac disorders Myocardial infarction, cardiac arrest, angina pectoris, tachycardia, bradycardia, palpitations, cyanosis Vascular disorders Hypotension, (deep vein) thrombosis, peripheral circulatory failure/collapse, hypertension, phlebitis, pallor Respiratory, thoracic and mediastinal disorders Apnea, Acute Respiratory Distress Syndrome (ARDS), TRALI, respiratory failure, pulmonary embolism, pulmonary edema, bronchospasm, dyspnea, hypoxia, wheezing, cough Gastrointestinal disorders Diarrhea, hepatic dysfunction, abdominal discomfort Skin and subcutaneous tissue disorders Eczema, urticaria, rash (erythematous), dermatitis, pruritus, alopecia, Stevens-Johnson syndrome, epidermolysis, skin exfoliation, erythema (multiform), dermatitis (e.g., bullous dermatitis) Musculoskeletal and connective tissue disorders Back pain, arthralgia, myalgia, musculoskeletal pain, muscle stiffness, pain in extremity, neck pain, muscle spasm Renal and urinary disorders Acute renal failure, osmotic nephropathy, renal pain General disorders and administration site conditions Injection-site reaction, chills, chest pain or discomfort, hot flush, flushing, flu-like illness, feeling cold or hot, edema, hyperhidrosis, malaise, asthenia, lethargy, burning sensation Investigations Hepatic enzymes increased, oxygen saturation decreased, falsely elevated erythrocyte sedimentation rate, positive direct antiglobulin (Coombs) test

adverse reactions table

<table ID="Table2"><caption>Table 2 Adverse Reactions* (ARs) (within 72 hours after the end of an ALYGLO infusion) in &#x2265; 5% of Subjects</caption><col width="227"/><col width="248"/><col width="248"/><tbody><tr><td styleCode="Toprule Lrule Rrule " align="center"><content styleCode="bold">Adverse</content><content styleCode="bold"> </content><content styleCode="bold">Reactions</content><content styleCode="bold"> </content><content styleCode="bold">(ARs)</content></td><td styleCode="Toprule Lrule Rrule " align="center"><content styleCode="bold">No.</content><content styleCode="bold"> of </content><content styleCode="bold">Subjects</content><content styleCode="bold"> </content><content styleCode="bold">Reporting</content><content styleCode="bold"> </content><content styleCode="bold">ARs</content> <content styleCode="bold">(Percentage</content><content styleCode="bold"> </content><content styleCode="bold">of</content><content styleCode="bold"> </content><content styleCode="bold">Subjects)</content> <content styleCode="bold">[N</content><content styleCode="bold"><sup>1</sup></content><content styleCode="bold">=33]</content></td><td styleCode="Toprule Lrule Rrule " align="center"><content styleCode="bold">No.</content><content styleCode="bold"> of </content><content styleCode="bold">Infusions</content><content styleCode="bold"> </content><content styleCode="bold">with</content><content styleCode="bold"> </content><content styleCode="bold">ARs</content> <content styleCode="bold">(Percentage</content><content styleCode="bold"> </content><content styleCode="bold">of</content><content styleCode="bold"> </content><content styleCode="bold">Infusions)</content> <content styleCode="bold">[N</content><content styleCode="bold"><sup>2</sup></content><content styleCode="bold">=427]</content></td></tr><tr><td styleCode="Toprule Lrule Rrule ">Headache</td><td styleCode="Toprule Lrule Rrule " align="center">13 (39)</td><td styleCode="Toprule Lrule Rrule " align="center">32 (7.5)</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Nausea/vomiting</td><td styleCode="Toprule Lrule Rrule " align="center">11 (33)</td><td styleCode="Toprule Lrule Rrule " align="center">20 (4.7)</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Fatigue</td><td styleCode="Toprule Lrule Rrule " align="center">6 (18)</td><td styleCode="Toprule Lrule Rrule " align="center">18 (4.2)</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Nasal/sinus congestion</td><td styleCode="Toprule Lrule Rrule " align="center">5 (15)</td><td styleCode="Toprule Lrule Rrule " align="center">5 (1.2)</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Rash</td><td styleCode="Toprule Lrule Rrule " align="center">4 (12)</td><td styleCode="Toprule Lrule Rrule " align="center">4 (0.9)</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Arthralgia</td><td styleCode="Toprule Lrule Rrule " align="center">3 (9)</td><td styleCode="Toprule Lrule Rrule " align="center">4 (0.9)</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Diarrhea</td><td styleCode="Toprule Lrule Rrule " align="center">3 (9)</td><td styleCode="Toprule Lrule Rrule " align="center">3 (0.7)</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Muscle pain/aches</td><td styleCode="Toprule Lrule Rrule " align="center">2 (6)</td><td styleCode="Toprule Lrule Rrule " align="center">7 (1.6)</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Infusion site pain/swelling</td><td styleCode="Toprule Lrule Rrule " align="center">2 (6)</td><td styleCode="Toprule Lrule Rrule " align="center">6 (1.4)</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Abdominal pain/discomfort</td><td styleCode="Toprule Lrule Rrule " align="center">2 (6)</td><td styleCode="Toprule Lrule Rrule " align="center">3 (0.7)</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Cough</td><td styleCode="Toprule Lrule Rrule " align="center">2 (6)</td><td styleCode="Toprule Lrule Rrule " align="center">2 (0.5)</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Dizziness</td><td styleCode="Toprule Lrule Rrule " align="center">2 (6)</td><td styleCode="Toprule Lrule Rrule " align="center">2 (0.5)</td></tr></tbody></table>

adverse reactions table

<table><col width="722"/><tbody><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">Blood</content><content styleCode="bold italics"> </content><content styleCode="bold italics">and</content><content styleCode="bold italics"> </content><content styleCode="bold italics">lymphatic</content><content styleCode="bold italics"> </content><content styleCode="bold italics">system</content><content styleCode="bold italics"> </content><content styleCode="bold italics">disorders</content> Leucopenia, hemolysis, pancytopenia</td></tr><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">Immune</content><content styleCode="bold italics"> </content><content styleCode="bold italics">system</content><content styleCode="bold italics"> </content><content styleCode="bold italics">disorders</content> Hypersensitivity (e.g., anaphylaxis), anaphylactic shock, anaphylactic reaction, anaphylactoid reaction, allergic reaction, angioedema, face edema</td></tr><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">Metabolic</content><content styleCode="bold italics"> </content><content styleCode="bold italics">and</content><content styleCode="bold italics"> </content><content styleCode="bold italics">nutritional</content><content styleCode="bold italics"> </content><content styleCode="bold italics">disorders</content> Fluid overload, (pseudo) hyponatremia</td></tr><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">Psychiatric</content><content styleCode="bold italics"> </content><content styleCode="bold italics">disorders</content> Agitation, confusion, anxiety, nervousness</td></tr><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">Nervous</content><content styleCode="bold italics"> </content><content styleCode="bold italics">system</content><content styleCode="bold italics"> </content><content styleCode="bold italics">disorders</content> Coma, loss of consciousness, seizures, (acute) encephalopathy, cerebrovascular accident, stroke, aseptic meningitis, migraine, speech disorder, paresthesia, hypoesthesia, photophobia, tremor</td></tr><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">Cardiac</content><content styleCode="bold italics"> </content><content styleCode="bold italics">disorders</content> Myocardial infarction, cardiac arrest, angina pectoris, tachycardia, bradycardia, palpitations, cyanosis</td></tr><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">Vascular</content><content styleCode="bold italics"> </content><content styleCode="bold italics">disorders</content> Hypotension, (deep vein) thrombosis, peripheral circulatory failure/collapse, hypertension, phlebitis, pallor</td></tr><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">Respiratory,</content><content styleCode="bold italics"> </content><content styleCode="bold italics">thoracic</content><content styleCode="bold italics"> </content><content styleCode="bold italics">and</content><content styleCode="bold italics"> </content><content styleCode="bold italics">mediastinal</content><content styleCode="bold italics"> </content><content styleCode="bold italics">disorders</content> Apnea, Acute Respiratory Distress Syndrome (ARDS), TRALI, respiratory failure, pulmonary embolism, pulmonary edema, bronchospasm, dyspnea, hypoxia, wheezing, cough</td></tr><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">Gastrointestinal disorders</content> Diarrhea, hepatic dysfunction, abdominal discomfort</td></tr><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">Skin</content><content styleCode="bold italics"> </content><content styleCode="bold italics">and</content><content styleCode="bold italics"> </content><content styleCode="bold italics">subcutaneous</content><content styleCode="bold italics"> </content><content styleCode="bold italics">tissue</content><content styleCode="bold italics"> </content><content styleCode="bold italics">disorders</content> Eczema, urticaria, rash (erythematous), dermatitis, pruritus, alopecia, Stevens-Johnson syndrome, epidermolysis, skin exfoliation, erythema (multiform), dermatitis (e.g., bullous dermatitis)</td></tr><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">Musculoskeletal</content><content styleCode="bold italics"> </content><content styleCode="bold italics">and</content><content styleCode="bold italics"> </content><content styleCode="bold italics">connective</content><content styleCode="bold italics"> </content><content styleCode="bold italics">tissue</content><content styleCode="bold italics"> </content><content styleCode="bold italics">disorders</content> Back pain, arthralgia, myalgia, musculoskeletal pain, muscle stiffness, pain in extremity, neck pain, muscle spasm</td></tr><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">Renal</content><content styleCode="bold italics"> </content><content styleCode="bold italics">and</content><content styleCode="bold italics"> </content><content styleCode="bold italics">urinary</content><content styleCode="bold italics"> </content><content styleCode="bold italics">disorders</content> Acute renal failure, osmotic nephropathy, renal pain</td></tr><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">General</content><content styleCode="bold italics"> </content><content styleCode="bold italics">disorders</content><content styleCode="bold italics"> </content><content styleCode="bold italics">and</content><content styleCode="bold italics"> </content><content styleCode="bold italics">administration</content><content styleCode="bold italics"> </content><content styleCode="bold italics">site</content><content styleCode="bold italics"> </content><content styleCode="bold italics">conditions</content> Injection-site reaction, chills, chest pain or discomfort, hot flush, flushing, flu-like illness, feeling cold or hot, edema, hyperhidrosis, malaise, asthenia, lethargy, burning sensation</td></tr><tr><td styleCode="Toprule Lrule Rrule "><content styleCode="bold italics">Investigations</content> Hepatic enzymes increased, oxygen saturation decreased, falsely elevated erythrocyte sedimentation rate, positive direct antiglobulin (Coombs) test</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.